CARM Carisma Therapeutics Inc
Price (delayed)
$0.2222
Market cap
$9.29M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.46
Enterprise value
-$6.14M
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is
Highlights
The company's EPS rose by 44% YoY and by 3.9% QoQ
The net income rose by 30% year-on-year and by 5% since the previous quarter
The company's revenue rose by 32% YoY but it fell by 3.1% QoQ
CARM's gross profit is up by 32% year-on-year but it is down by 3.1% since the previous quarter
The equity has shrunk by 151% QoQ
Carisma Therapeutics's quick ratio has plunged by 77% YoY and by 56% from the previous quarter
Key stats
What are the main financial stats of CARM
Market
Valuations
Earnings
Shares outstanding
41.79M
Market cap
$9.29M
Enterprise value
-$6.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.31
Revenue
$19.63M
Gross profit
$19.63M
Operating income
-$62.18M
Net income
-$60.48M
EBIT
-$60.48M
EBITDA
-$52.16M
Free cash flow
-$60.04M
Per share
Balance sheet
Liquidity
EPS
-$1.46
EPS diluted
-$1.46
Free cash flow per share
-$1.45
Book value per share
-$0.67
Revenue per share
$0.47
TBVPS
$0.73
Total assets
$30.46M
Total liabilities
$58.37M
Debt
$2.48M
Equity
-$27.91M
Working capital
$7.77M
Debt to equity
-0.09
Current ratio
1.48
Quick ratio
1.12
Net debt/EBITDA
0.3
Margins
Efficiency
Dividend
EBITDA margin
-265.7%
Gross margin
100%
Net margin
-308.1%
Operating margin
-316.7%
Return on assets
-117.6%
Return on equity
N/A
Return on invested capital
-942.7%
Return on capital employed
-419.9%
Return on sales
-308.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CARM stock price
How has the Carisma Therapeutics stock price performed over time
Intraday
-3.6%
1 week
-42.3%
1 month
-44.59%
1 year
-88.95%
YTD
-46.94%
QTD
-28.32%
Financial performance
How have Carisma Therapeutics's revenue and profit performed over time
Revenue
$19.63M
Gross profit
$19.63M
Operating income
-$62.18M
Net income
-$60.48M
Gross margin
100%
Net margin
-308.1%
The operating margin is up by 47% year-on-year and by 3.9% since the previous quarter
The net margin has grown by 47% YoY and by 2.1% from the previous quarter
The company's revenue rose by 32% YoY but it fell by 3.1% QoQ
CARM's gross profit is up by 32% year-on-year but it is down by 3.1% since the previous quarter
Growth
What is Carisma Therapeutics's growth rate over time
Valuation
What is Carisma Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.31
The company's EPS rose by 44% YoY and by 3.9% QoQ
The equity has shrunk by 151% QoQ
The price to sales (P/S) is 96% lower than the 5-year quarterly average of 10.9 and 84% lower than the last 4 quarters average of 3.0
The company's revenue rose by 32% YoY but it fell by 3.1% QoQ
Efficiency
How efficient is Carisma Therapeutics business performance
CARM's ROA has dropped by 64% year-on-year and by 22% since the previous quarter
The company's return on sales rose by 47% YoY and by 4% QoQ
The return on invested capital has increased by 6% since the previous quarter
Dividends
What is CARM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CARM.
Financial health
How did Carisma Therapeutics financials performed over time
Carisma Therapeutics's total assets is 48% lower than its total liabilities
Carisma Therapeutics's quick ratio has plunged by 77% YoY and by 56% from the previous quarter
Carisma Therapeutics's current ratio has shrunk by 71% YoY and by 54% QoQ
The debt is 109% more than the equity
CARM's debt to equity has shrunk by 175% YoY but it has soared by 70% QoQ
The equity has shrunk by 151% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.